Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study
| العنوان: | Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study |
|---|---|
| المؤلفون: | Hellemond, I.E.G. van, Smorenburg, C.H., Peer, P.G.M., Swinkels, A.C.P., Seynaeve, C.M., Sangen, M.J.C. van der, Kroep, J.R., Graaf, H. de, Honkoop, A.H., Erdkamp, F.L.G., Berkmortel, F.W.P.J. van den, Boer, M. de, Roos, W.K. de, Linn, S.C., Imholz, A.L.T., Tjan-Heijnen, V.C.G., Dutch Breast Canc Res Grp BOOG |
| المساهمون: | Medical Oncology, Otorhinolaryngology and Head and Neck Surgery, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), Interne Geneeskunde, Promovendi ODB, MUMC+: MA Medische Oncologie (9) |
| المصدر: | International Journal of Cancer, 145(5), 1325-1333. Wiley-Liss Inc. International Journal of Cancer International Journal of Cancer, 145(5), 1325-1333. Wiley International Journal of Cancer, 145(5), 1325-1333. WILEY International Journal of Cancer, 145, 1325-1333 International Journal of Cancer, 145, 5, pp. 1325-1333 |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Cancer Research, medicine.medical_treatment, Osteoporosis, TERM DENOSUMAB TREATMENT, THERAPY, aromatase inhibitors, DOUBLE-BLIND, Fractures, Bone, 0302 clinical medicine, Bone Density, Medicine, Prospective Studies, Cancer Therapy and Prevention, Osteoporosis, Postmenopausal, tamoxifen, ADJUVANT LETROZOLE, Middle Aged, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Oncology, POSTMENOPAUSAL WOMEN, PREMENOPAUSAL WOMEN, 030220 oncology & carcinogenesis, ZOLEDRONIC ACID, Female, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, anastrozole, Anastrozole, Breast Neoplasms, 03 medical and health sciences, Breast cancer, breast cancer, adjuvant, SDG 3 - Good Health and Well-being, Internal medicine, Humans, bone health, Aromatase inhibitor, business.industry, endocrine therapy, Bisphosphonate, medicine.disease, osteoporosis, Osteopenia, Zoledronic acid, osteopenia, AROMATASE INHIBITOR, MINERAL DENSITY, business, bone mineral density, Tamoxifen |
| الوصف: | The phase III DATA study investigates the efficacy of adjuvant anastrozole (6 vs. 3 year) in postmenopausal women with breast cancer previously treated with 2–3 years of tamoxifen. This planned side‐study assessed patterns of care regarding detection and treatment of osteopenia/osteoporosis, and trends in bone mineral density (BMD) during and after therapy. We registered all BMD measurements and bisphosphonate‐use. Time to osteopenia/osteoporosis was analysed by Kaplan Meier methodology. For the trend in T‐scores we used linear mixed models with random patients effects. Of 1860 eligible DATA patients, 910 (48.9%) had a baseline BMD measurement. Among patients with a normal baseline BMD (n = 417), osteopenia was observed in 53.5% and 55.4% in the 6‐ and 3‐year group respectively (p = 0.18), during follow‐up. Only two patients (3‐year group) developed osteoporosis. Of the patients with osteopenia at baseline (n = 408), 24.4% and 20.4% developed osteoporosis respectively (p = 0.89). Three years after randomisation 18.3% and 18.2% used bisphosphonates in the 6‐ and 3‐year groups respectively and 6 years after randomisation this was 23.7% and 20.9% respectively (p = 0.90) of which the majority used oral bisphosphonates. The yearly mean BMD‐change during anastrozole in the lumbar spine showed a T‐score decline of 0.075. After bisphosphonate addition the decline became less prominent (0.047 (p What's new? Loss of bone mineral density (BMD) is a side effect of aromatase inhibitor treatment, a class of drugs that stops estrogen production in postmenopausal women with breast cancer. Here the authors examined BMD loss during and after extended adjuvant endocrine therapy, following a 2‐3 year treatment with tamoxifen, subsequent aromatase inhibitor treatment was associated with BMD decrease, but the decline was modest and partially reversible after treatment cessation. The authors concluded that extended endocrine therapy was not associated with a higher incidence of osteoporosis. |
| وصف الملف: | application/pdf |
| تدمد: | 0020-7136 1325-1333 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0d75c26646b7999037a83fd370e350Test https://doi.org/10.1002/ijc.32205Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6c0d75c26646b7999037a83fd370e350 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00207136 13251333 |
|---|